, a peptide corresponding to the 317-326 sequence of p120 RasGAP coupled with a cell-permeable TAT-derived peptide, sensitizes the death response of various tumor cells to several anticancer treatments. We now report that this peptide is also able to increase cell adherence, prevent cell migration and inhibit matrix invasion. This is accompanied by a marked modification of the actin cytoskeleton and focal adhesion redistribution. Interestingly, integrins and the small Rho GTP-binding protein, which are well-characterized proteins modulating actin fibers, adhesion and migration, do not appear to be required for the pro-adhesive properties of TAT-RasGAP 317-326 . In contrast, deleted in liver cancer-1, a tumor suppressor protein, the expression of which is often deregulated in cancer cells, was found to be required for TAT-RasGAP 317-326 to promote cell adherence and inhibit migration. These results show that TAT-RasGAP 317-326 , besides its ability to favor tumor cell death, hampers cell migration and invasion.
INTRODUCTION
Cancer is the second leading cause of mortality worldwide. 1 A hallmark of tumor cells is their ability to acquire an invasive phenotype and metastasize from the primary tumor. 2 Metastasis accounts for more than 90% of cancer-related death.
1,2 Metastatic dissemination begins with a cellular reprogramming that allows tumor cells to escape from the primary tumor to undertake a long migration journey through tissues and in the vascular and lymphatic circulation. 3, 4 Metastatic cells are characterized by their ability to degrade the extracellular matrix at the primary site and the new colonization site and to undergo intravasation and extravasation into or from the blood and/or lymph vessels. 5 Although the molecular events during the metastatic cascade are now relatively well understood, there are no tools yet to effectively inhibit the critical steps of the metastatic cascade and, eventually, metastasis formation. 6 A hallmark of metastatic progression and invasiveness is increased cell motility. 7, 8 Cell migration is a complex multistep and spatiotemporally organized process. It involves the integration of signals that define cell polarity, dynamic remodeling of cytoskeleton and focal adhesion (FA) structures as well as the regulation of the adhesive interaction with the extracellular environment. 8 FAs are structures that link the exterior of the cell to the cytoskeleton through integrin transmembrane proteins. On the one hand, FAs allow the cells to anchor on its extracellular matrix and on the other hand they modulate various signaling events involved in cell migration. 9 Small GTPases of the Rho family, in particular RhoA, Rac1 and Cdc42, are typically triggered by integrin engagement and finely coordinate cell migration at all levels. 10 For example, in addition to their central function on actin dynamics regulation, Rac1 and RhoA trigger FA formation and maturation, respectively. 11 Any impairment in these steps can result in an inefficient motility and therefore can compromise metastatic progression. From a therapeutic point of view, inhibiting cell migration is a logical approach for the development of anti-metastatic drugs as it is an early event in metastatic progression.
Dysregulation of pathways regulating actin cytoskeleton dynamics and cell migration is often required for cancer cell to attain their full oncogenic potential. 7 This can be so crucial for tumor development that some proteins modulating these pathways are in fact tumor suppressors, such as neurofibromatosis type-2 (NF2) 12 and adenomatous polyposis coli (APC). 13 One other such tumor suppressor is deleted in liver cancer-1 (DLC1), a RhoGAP protein acting on Rho and Cdc42.
14 DLC1 is mutated almost as often as p53 suggesting that it is a major player during cancer progression. 15 Its reintroduction in DLC1-negative cancer cells was reported to inhibit their tumorigenicity and invasive behavior in a Rho-dependent and Rho-independent manner. 16 The Rasa1 gene product p120 RasGAP (from now on referred to as RasGAP) is a negative modulator of the Ras small GTPase. RasGAP can also interact with a large number of other proteins via proline-rich, Src homology (SH), pleckstrin homology and C2 domains. 17 We previously reported that full cleavage of RasGAP by caspase-3 leads to the generation of fragment N2 (RasGAP ) that efficiently and specifically sensitizes cancer cells to a panel of anticancer therapy-induced cell death. 18 The shortest region responsible for this effect resides in a 10-amino-acid sequence (RasGAP 317-326 ) within the SH3 domain. 19 TAT-RasGAP 317-326 corresponds to this sequence hooked to a cell-permeable TATderived peptide and synthesized with D-amino acids. TATRasGAP 317-326 sensitizes a variety of tumor cells to genotoxinand photodynamic therapy-induced death, both in vitro and in vivo. [19] [20] [21] [22] Importantly, it does not affect normal cells. 19, 21 In the present report, we show that TAT-RasGAP 317-326 increases cell adhesiveness and inhibits cell migration and invasion in a DLC1-dependent manner.
RESULTS
TAT-RasGAP 317-326 increases cell adhesiveness By serendipity, we discovered that TAT-RasGAP 317-326 has a marked effect on cell adhesion to their substratum. Incubation of the U2OS human osteosarcoma cell line with TAT-RasGAP 317-326 , but not with the TAT cell-permeable sequence alone, rendered it resistant to cell detachment by trypsin/EDTA in a time-dependent manner ( Figure 1a) . Three hours after incubation with the RasGAPderived peptide, approximately 50% of the cells became resistant to detachment. The percentage of non-detachable cells increased to 90% after 8 h of treatment. The TAT-RasGAP 317-326 -induced resistance to trypsin/EDTA was also observed in seven other cancer and non-cancer cell lines (Figure 1b) . This phenotype was found to be reversible 4-6 h following removal of the peptide (Figure 1c) . TAT-RasGAP 317-326 rendered U2OS cells resistant not only to trypsin-mediated detachment but also to EDTA-mediated detachment (Figure 1d ). This indicates that the mechanism allowing TAT-RasGAP 317-326 to block cell detachment is not due to a potential inhibitory activity on trypsin. An adhesion assay was further performed to evaluate the effect of TAT-RasGAP 317-326 on the adhesion speed ( Figure 1e and Supplementary Figure S1A ). It revealed that the RasGAP-peptide was not only negatively impinging on detachment but also significantly increased the cell adhesion rate. Although the TAT peptide alone induced a statistically significant higher adhesion speed over untreated cells, TAT-RasGAP 317-326 stimulated an even faster cell adhesion rate. Of note, this adhesion was already detectable 30 min after the addition of the peptide, but at this time point the cells have not yet acquired their ability to resist trypsin-mediated detachment (see Supplementary Figure  S1B ). TAT-RasGAP 317-326 -treated cells displayed a spread phenotype in comparison with TAT and untreated cells (Supplementary Figure S1C) . The increase in cell adhesion was confirmed using a flow-mediated detachment assay. Untreated and TAT-treated HeLa cells were detachable by a strong (400 ml/s) and by a weaker (120 ml/s) flow. In contrast, although Figure S2A) and to increase the adhesion rate (Supplementary Figure S2B) . Adhesiveness was also increased when TAT was replaced with another cell-permeable sequence, R9, a peptide composed of nine arginine residues (Supplementary Figure S2A) Figure S2C) . This indicates that the peptide can be part of a larger polypeptide and still exerts its detachment resistance activity. These data provide new insights of a potential physiological function of fragment N2 that is generated upon high caspase-3 activity. 18 Taken together, these results suggest that TAT-RasGAP 317-326 triggers intracellular signaling pathways regulating cell adhesion.
TAT-RasGAP 317-326 mediates increased cell adherence through posttranslational effects Next, the requirement of transcription and translation for the capacity of TAT-RasGAP 317-326 to increase cell adhesion was evaluated. U2OS cells were treated with actinomycin D, to block transcription, or with cycloheximide, to block translation, and were then subjected to a trypsin-mediated detachment assay (Supplementary Figure S3A) . These drugs efficiently inhibited transcription and translation as assessed by the disappearance of the short-lived c-Myc protein (Supplementary Figure S3A) . In these conditions, TAT-RasGAP 317-326 was still able to increase adherence, indicating that the peptide acts posttranslationally. The involvement of the proteasome was then tested. As shown in Supplementary Figure S3B (upper graph), the MG-132 proteasome inhibitor did not affect the capacity of TAT-RasGAP 317-326 to prevent cell detachment despite being able to inhibit cycloheximide-induced c-Myc degradation (Supplementary Figure S3B ; lower blot). The observation that staurosporine, a compound able to inhibit B90% of all kinases, 24 did not affect TAT-RasGAP 317-326 -induced increased adhesiveness (Supplementary Figure S3C) indicates that most kinases are not mediating the effect of the RasGAP-derived peptide. The RasGAP SH3 domain that harbors the RasGAP 317-326 sequence has the potential to dimerize 25 raising the possibility that TAT-RasGAP 317-326 interacts with RasGAP or RasGAP-derived fragments and that such an interaction is required for the peptide to render cells resistant to detachment. However, RasGAP knockout mouse embryonic fibroblasts (MEFs) became resistant to trypsin-mediated detachment when incubated with TAT-RasGAP 317-326 (Supplementary Figure S3D) . Therefore, the RasGAP-derived peptide does not require the endogenous wildtype molecule (i.e., RasGAP) to mediate its cellular effects on adhesion.
Integrins and CD44 adhesion receptors are not required for TAT-RasGAP 317-326 -mediated increased cell adhesiveness We investigated whether TAT-RasGAP 317-326 requires integrin functions. Integrins are heterodimers composed of one a and one b subunit. There are 18 different known a and b subunits that can combine to form 24 different heterodimers. 9 About 70% (16 out of 24) of these integrin dimers are made of either the a V -or the b1-integrins (Supplementary Figure S4A) . The fact that a melanoma cell line deficient in a V -integrin expression 26 was rendered more adherent by TAT-RasGAP 317-326 (Supplementary Figure S4B ) together with the observation that b1-integrin silencing in HeLa cells did not prevent TAT-RasGAP 317-326 from triggering adherence (Supplementary Figure S4C) suggests, however, that these widespread integrins do not individually mediate the pro-adhesive phenotype induced by TAT-RasGAP 317-326 . It is unlikely that other integrins are targeted by the RasGAP peptide to mediate its effects on adhesion for the following reasons: (i) b2-, b3-, b4-and b7-integrins are expressed at very low levels or are not detected in U2OS cells (Supplementary Figure  S4D ) 27 that are responsive to TAT-RasGAP 317-326 ; (ii) the TAT-RasGAP 317-326 inhibits migration and invasion D Barras et al expression of b2-and b7-integrin is usually restricted to immune cells. 28 We also tested the involvement of the CD44 glycoprotein, a FA-independent adhesion receptor that can also interact with ECM. 29 However, upon CD44 silencing in HeLa cells, TATRasGAP 317-326 could still increase adhesion (Supplementary Figure S4E) . Consistent with our results on integrins are the data showing that TAT-RasGAP 317-326 -mediated adhesion does not occur through a specific ECM as cell adhesion to collagen, fibronectin and laminin was increased by the RasGAP peptide (Supplementary Figure S4F) . Altogether, the results indicate that CD44, b1-integrin and a v -integrin are individually dispensable for the adhesion-activating effect of TAT-RasGAP 317-326 .
TAT-RasGAP 317-326 remodels FAs and induces actin depolymerization FAs are protein complexes through which the cytoskeleton is connected to the extracellular matrix and as such could be modulated by TAT-RasGAP 317-326 to increase cell adhesion. Focal adhesion kinase (FAK), when recruited to activated integrins, acts as a key protein during FA formation and turnover. For example, it regulates the dynamics of actin fibers by favoring actin polymerization through phosphorylation of N-WASP, actin contraction via activation of p190 RhoGEF and actin fiber fluidity by phosphorylating a-actinin and inhibiting its actin cross-linking capacity. 30 Even though FAK-null cells are still able to form FAs, FAK recruitment to integrins remains a typical feature of FA formation and subsequent attachment to the actin cytoskeleton. 30, 31 To assess FA modulation and actin polymerization upon TAT-RasGAP 317-326 treatment, U2OS cells were labeled with antibodies specific for FAK, phospho-Tyr 397 -FAK or stained for filamentous actin (F-actin). A marked increase in cortical actin fibers forming peripheral concentric arc-like structures (Figure 3a ; white arrows) was induced by the RasGAPderived peptide, whereas stress fibers almost completely disappeared (Figure 3a; yellow arrows) . Unexpectedly, the overall number of FAs decreased, and there was a redistribution of FAs to the cell periphery. In addition, TAT-RasGAP 317-326 treatment resulted in significant dephosphorylation of FAK at tyrosine 397, which indicates a reduction in FA turnover. 32 The expression levels of the FA-associated FAK and vinculin proteins, or the cytoskeletal b-actin and a-tubulin, were not affected by the RasGAP-derived peptide (Figure 3b) . The a-tubulin network was also not affected by TAT-RasGAP 317-326 (data not shown). Figure 3c shows that, using FAK knockout MEFs, the absence of FAK did not prevent TAT-RasGAP 317-326 to increase adherence, excluding FAK as being the target of the RasGAP-derived peptide. Because TAT-RasGAP 317-326 -treated cells exhibited a loss of stress fibers, the effect of the peptide on actin fiber dynamics was investigated by measuring the ratio between polymerized F-actin and monomeric G-actin. Figure 4a shows that the F/G-actin ratio was significantly decreased upon TAT-RasGAP 317-326 treatment to values similar as those obtained when known actin inhibitors (latrunculin A and cytochalasin D) were used. Interestingly, similar to TAT-RasGAP 317-326 , both latrunculin A and cytochalasin D increased cell adhesion, whereas jasplakinolide, an actin polymerization inducer, did not (Figure 4b ). This suggests that actin depolymerization is involved in TAT-RasGAP 317-326 -mediated cell adhesion increase. An in vitro pyrene-actin-based polymerization assay revealed, however, that RasGAP 317-326 alone does not slow down actin polymerization (Figure 4c ), indicating that TATRasGAP 317-326 -mediated actin depolymerization in cells is indirect.
TAT-RasGAP 317-326 does not require the Rho/ROCK axis to increase cell adhesiveness As the SH3 domain of RasGAP has been shown to remodel the actin cytoskeleton in a Rho-dependent manner, 33 we investigated whether the activity of Rho could be modulated by the RasGAPderived peptide. The level of the active GTP-bound RhoA, the main Rho family member, was assessed by performing a pulldown assay using the Rho-binding domain (RBD) of the Rhotekin protein that specifically binds to GTP-RhoA. 34 TAT-RasGAP 317-326 -pretreated cells exhibited a significantly higher peak of Rho activation after 1 min of serum exposure (Figure 5a ). These results show that, albeit only transiently, TAT-RasGAP 317-326 modulates Rho activation. RasGAP and p190RhoGAP have been previously reported to form a complex, the biological relevance of which is thought to coordinate Ras-and Rho-mediated signaling pathways. 35 The possibility that TAT-RasGAP 317-326 disrupts this complex was evaluated. Supplementary Figure S5 shows that the RasGAP-RhoGAP interaction was not modulated by the RasGAP peptide, suggesting that the increase in RhoA activity by TAT-RasGAP 317-326 was not modulated at this level. This result is also consistent with the fact that the RasGAP-derived peptide does not require full-length RasGAP to mediate its effects (see Supplementary Figure S3D ).
To further understand whether the TAT-RasGAP 317-326 -mediated transient RhoA activation was needed for the increase in cell adherence, a trypsin-mediated detachment assay was performed in the absence or in the presence of the Botulinum C3 exoenzyme Rho inhibitor or Y-27632, an inhibitor of ROCK, an effector of Rho. Treatment with both drugs did not prevent TAT-RasGAP 317-326 from increasing adherence, indicating that this peptide does not mediate an increase in adhesion through activation of the Rho-ROCK pathway (Figure 5b ). TAT-RasGAP 317-326 also prevented cell shrinking/rounding induced by the C3 exoenzyme (Figure 5c ), a possible consequence of its capacity to increase adhesiveness.
TAT-RasGAP 317-326 impairs cell migration and invasion It has been reported that a strong adhesion of cells to their substratum correlates with poor migration. 36 These observations raise the possibility that TAT-RasGAP 317-326 affects cell migration. Scratch wound healing assays were used to evaluate this assumption. Four different cancer and non-cancer cell lines (U2OS, HCT116, HeLa and HaCaT) were wounded and simultaneously treated or not with the TAT or TAT-RasGAP 317-326 peptides. A 48 h period of time was sufficient for untreated and 
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TAT-only treated cells to fill the wounds entirely, whereas TATRasGAP 317-326 -treated cells exhibited highly impaired motility (Figure 6a ; time-lapse movie in Supplementary Material). This observation was further confirmed using a transwell Boyden chamber migration assay in which TAT-RasGAP 317-326 recapitulated the inhibition on cell migration (Figure 6b) . Because RasGAP modulates cell proliferation through Ras, we assessed whether TAT-RasGAP 317-326 affects cell proliferation to rule out the possibility that impaired migration was a consequence of decreased proliferation. However, the peptide did not impair proliferation of adherent cells (Supplementary Figure S6A) or cells in suspension (Supplementary Figure S6B) . These results were confirmed by testing the ability of U2OS cells to incorporate radioactive thymidine in the presence of TAT-RasGAP 317-326 (Supplementary Figure S6C) . As migration is a hallmark of invasiveness, we tested whether TAT-RasGAP 317-326 could hamper cell invasion. Using a transwell Boyden chamber layered with an extracellular matrix gel, it was found that TAT-RasGAP 317-326 also prevented invasion of MDA-MB-231 cells ( Figure 6C ). DLC1 is required for TAT-RasGAP 317-326 -mediated migration inhibition Several RasGAP binding partners have been identified in the past. 17 Among them, DLC1, a RhoGAP with tumor and metastasis suppressor activities, binds the SH3 domain of RasGAP via its GAP domain. 14, 37 The reported consequence of this binding is an inhibition of the DLC1 RhoGAP activity and impairment of its oncosupppressive activity. Fragment N2, the RasGAP 317-326 -containing polypeptide that is physiologically generated by high levels of caspase-3 23 and that increases cell adhesion (Supplementary Figure S2C) was also able to interact with DLC1 ( Figure 7a ). However, an alanine substitution of tryptophan 317, an evolutionarily conserved residue within the RasGAP 317-326 sequence, abrogated the ability of fragment N2 to bind to DLC1 (Figure 7a) . A TAT-RasGAP 317-326 peptide version bearing the W317A mutation failed to increase cell adherence (Figure 7b ). These results indicate that the interaction of tryptophan 317 with DLC1 is essential for TAT-RasGAP 317-326 -mediated effects on cell adhesiveness.
The involvement of DLC1 in the pro-adhesion and antimigratory functions of TAT-RasGAP 317-326 was assessed in DLC1 knockout MEFs. In contrast to wild-type MEFs, DLC1-null MEFs were efficiently detached by trypsin despite the presence of TATRasGAP 317-326 (Figure 7c) . Moreover, TAT-RasGAP 317-326 did not, or only minimally, hamper migration of DLC1-null cells, in contrast again to wild-type MEFs that were unable to migrate into wounds in the presence of the peptide (Figure 7d) . To exclude the possibility that the inability of the DLC1 knockout MEFs to respond to TAT-RasGAP 317-326 was caused by something else than the absence of DLC1, the DLC1-null cells were transfected with a DLC1-encoding plasmid together with a GFP-encoding plasmid to label and track the transfected cells. Figure 7e shows that the transfected cells, in contrast to the non-transfected ones, were markedly impaired in the ability to migrate into wounds in the presence of TAT-RasGAP 317-326 . Altogether, these experiments demonstrate that the RasGAP-derived peptide requires DLC1 to exert its pro-adhesion and anti-migratory activities.
DISCUSSION
Blocking invasion is a prime strategy to inhibit the initial steps of the metastatic dissemination. In this study, we found that TAT-RasGAP 317-326 , previously shown to sensitize cancer cells to various anticancer treatments, [19] [20] [21] potently inhibits cell migration and invasion by targeting the DLC1 tumor suppressor.
Earlier reports have indicated that RasGAP can control cell migration. RasGAP knockout MEFs exhibit reduced migration, whereas RasGAP silencing in breast cancer cells enhances their motility. 38, 39 These conflicting results could be a consequence of the different cellular systems investigated. Another possibility is that the dosage of RasGAP reduction influences the resulting effect on migration. It can be envisioned that RasGAP both positively and negatively regulates cell migration, possibly in response to different stimuli, but that the negative regulation requires high level of expression of the protein. In this case, the Figure S3) . It is therefore likely that if full-length RasGAP and TAT-RasGAP 317-326 use the same pathway to regulate cell adhesion, it is a consequence of targeting the same molecules and not the result of the peptide modulating the activity of the parental RasGAP protein.
The SH3 domain of RasGAP can reorganize actin cytoskeleton in a Rho-dependent manner, 33, 38 presumably via the recruitment of p190RhoGAP. 35, 38 TAT-RasGAP 317-326 can also favor Rho activation, at least transiently ( Figure 5 ), but this apparently is not required for its capacity to increase cell adherence as inhibition of Rho or the Rho effector ROCK does not affect TATRasGAP 317-326 -mediated cell adhesiveness increase.
Although a V -and b1-integrins were not individually required, TAT-RasGAP 317-326 may nevertheless exert its effects through FA modulation. Rac-induced formation of nascent FAs can generate huge adhesive forces, 11 raising the hypothesis that the RasGAP-derived peptide prevents FA maturation, therefore retaining FAs in their hyper-adherent state. Consistent with this hypothesis are the observations that TAT-RasGAP 317-326 induced FAK dephosphorylation and relocation of FAs to the cell periphery (Figure 3) , which is typical of FA turnover inhibition. 11 The involvement of other adhesion receptors in TAT-RasGAP 317-326 -mediated adherence, such as syndecans and cell-adhesion molecules (CAMs), remains to be investigated. How can DLC1-dependent signaling increase adherence? The fact that DLC1 is located at FAs, 41 where it binds tensin, talin and FAK, 42 is certainly appropriate for a potential effect on adhesion and cell migration. DLC1 has indeed been shown to inhibit migration, both in Rho-dependent and Rho-independent ways. 14 However, as mentioned above, the peptide seems to exert its effects even when Rho is inhibited indicating that the peptide triggers a Rho-independent DLC1-mediated signaling. Such signaling could involve the PLCd1 phospholipase. DLC1 binds to and positively regulates PLCd1, which results in PIP 2 hydrolysis. 43 PIP 2 activates actin polymerization through various mechanisms [reviewed in Yin and Janmey 43 ] , and its hydrolysis leads to actin depolymerization, a response indeed induced by TAT-RasGAP 317-326 ( Figure 4 ). An attractive possibility is that TAT-RasGAP 317-326 by interacting with DLC-1 prevents the binding of the latter to PLCd1, thereby decreasing PLCd1 hydrolyzing activity and leading to À / À MEFs were co-transfected with a plasmid encoding GFP and with either a DLC1-encoding plasmid or the empty pcDNA3 vector. The cells were then subjected to a 24 h wound-healing scratch assay in the presence or in the absence of 20 mM TAT or TAT-RasGAP 317-326 . The migration was calculated as the number of GFP-positive cells that migrated through the initial wound made at 0 h (yellow dotted lines). Scale bar: 100 mm.
TAT-RasGAP 317-326 inhibits migration and invasion D Barras et al actin depolymerization and inhibition of migration. This would also induce peripheral FA redistribution, 32 a phenotype that is seen in TAT-RasGAP 317-326 -treated cells (Figure 3) . The fact that displacing DLC1 from FAs, through abrogation of FAK and tensin binding, does not affect the DLC1 RhoGAP activity 42 is consistent with our observation that Rho activity is not markedly modulated by TAT-RasGAP 317-326 ( Figure 5 ). DLC1 may not be the only target of the RasGAP-derived peptide as some residual attachment was observed in TAT-RasGAP 317-326 -treated DLC1-null MEFs (Figure 7 ). For example, proteins sharing redundancy with DLC1, such as DLC2 and DLC3, may partially compensate for the lack of DLC1. The involvement of such proteins in TAT-RasGAP 317-326 functions remains to be investigated.
The present study identifies TAT-RasGAP 317-326 as an activator of cell adhesion and an inhibitor of cell migration and invasion. Earlier work has shown that this RasGAP-derived peptide increases the death of tumor cells induced by various anticancer treatments. [19] [20] [21] Therefore, TAT-RasGAP 317-326 could exert two beneficial effects as an anticancer agent, first by increasing the sensitivity of tumor cells to anticancer drugs and second by reducing the invasive potential of tumor cells. Peptide synthesis and treatment and plasmids All peptides are described and were synthesized as previously reported. 19 The R9 and R9-RasGAP 317-326 peptides were kind gifts from Dr Christoph Kü ndig (MedDiscovery, Geneva, Switzerland). Plasmid description is detailed in the Supplementary Methods.
MATERIALS AND METHODS

Detachment assay
Cells were cultured until 80% confluence was reached and were treated as indicated in the figures. After a phosphate-buffered saline (PBS) wash, the non-trypsinized cells were directly colored with the Giemsa stain. The other cells were incubated with 5 g/l trypsin, 15 mM EDTA solution or with trypsin/EDTA (5 g/l trypsin, 6.8 mM EDTA) for 5 min. The cells were then washed once with phosphate-buffered saline and colored with the Giemsa stain. Four pictures per plate were taken using a Zeiss Axioplan 2 microscope equipped with a 10 Â objective. The number of adherent cells was then counted for each picture and expressed as the number of cells per mm 2 or alternatively as the percentage of adherent cells over the non-trypsinized control. The flow-mediated detachment assay is precisely described in the Supplementary Methods.
Adhesion assay U2OS cells were allowed to adhere with the indicated compounds for the indicated periods of time. The medium was then aspirated and the cells were gently washed once with phosphate-buffered saline and colored with the Giemsa stain. The data were collected as for detachment assays.
Western blot analysis
Cells were treated as indicated in the figures and western blots were performed as previously described. 19 Unless otherwise mentioned, 40 mg of proteins were loaded.
Wound-healing scratch assay, transwell migration and invasion assays Wound-healing scratch assays were performed as described earlier 45 and details are described in the Supplementary Methods. For the transwell migration assay, 50,000 overnight-starved 4T1 cells were seeded in the upper chamber of 24 transwell plates (Corning, Corning, NY, USA) for 2.5 h. The cells were then subjected to the treatments indicated in the figures for 3 h. DMEM complemented or not with 10% FBS was then placed in the lower chamber of the transwell plates, and the cells were allowed to migrate for 24 h. Cells that migrated through the filters were quantified as described in the Supplementary Methods.
For the transwell invasion assay, overnight-starved MDA-MB-231-luc cells were pre-treated for 2 h with 20 mM TAT, 20 mM TAT-RasGAP 317-326 or left untreated. A total of 5000 cells were resuspended in 100 ml of 4 mg/ml Matrigel (BD Biosciences, San Jose, CA, USA) complemented or not with 20 mM TAT, 20 mM TAT-RasGAP 317-326 , and placed in the top chamber. DMEM complemented or not with 10% FBS was then placed in the bottom chamber, and the cells were allowed to migrate through the filter for 48 h. The crystal-violet-colored invading cells were then counted for each condition and the results were expressed as the percentage of invading cells per transwell over the 'control þ serum' condition.
Statistical analysis
Unless otherwise mentioned, all experiments were performed three times and independently. The results were always expressed as mean±95% confidence intervals. Unless otherwise mentioned, Student's t-tests were performed to assess significant differences and using the appropriate Microsoft Excel function. The Bonferroni correction was applied when more than one comparison was performed. One-way and repeatedmeasurement ANOVAs were performed using the R software (Vienna, Austria; version 2.11.0) and were followed by a Tukey test for multiple comparisons. Asterisks denote statistical significant differences (P-valueo0.05).
